Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06930755 · ClinicalTrials.gov registry record · Phase 1
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
A Phase 1 study of Ovarian Cancer, sponsored by Nerviano Medical Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT06930755: Recruiting Phase 1 study of Ovarian Cancer, sponsored by Nerviano Medical Sciences.
NCT06930755 is a Phase 1 study of Ovarian Cancer that is actively recruiting participants, run by Nerviano Medical Sciences. The registered enrollment target is 24 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06930755, a Phase 1 study of Ovarian Cancer, is actively recruiting participants, sponsored by Nerviano Medical Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Primary Outcome
Evaluation of type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version 5.0), duration of AEs, first cycle DLT, electrocardiogram (ECG) and laboratory abnormalities and relationship of AE to study treatment
Conditions Studied
Interventions
- DRUG NMS-03305293
- DRUG Topotecan
Study Locations (5)
Illinois
- OSF Saint Francis Medical Center - Peoria
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Pennsylvania
- Penn Medicine - Perelman Center for Advanced Medicine - Philadelphia
Tennessee
- Tennessee Oncology - Nashville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-01-31 |
| Est. Completion | 2027-09-26 |
| Phase | Phase 1 |
What NCT06930755 shows while recruiting
NCT06930755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which NMS-03305293 is the first listed.
NCT06930755 lists 5 locations in 5 states (Illinois, Missouri, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06930755 about?
NCT06930755 is a clinical study titled "Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer". This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to eva...
What is the current status of trial NCT06930755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-01-31. Estimated completion is 2027-09-26.
What conditions does trial NCT06930755 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06930755?
The interventions under investigation include: NMS-03305293 (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT06930755?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06930755 being conducted?
This trial has 5 study locations across Illinois, Missouri, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06930755's enrollment target sits among peer trials
24 269th of 322 higher than 49 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI